Good idea, but alas I think it will never happen. There's a good case for a big chunk of listed biotech wannabes being forced private, delisted or merged, but ego, vested interests and money-go-round gravy trains always seem to get in the way.
AT1 and LDX have good ideas, but turning those ideas into sustainable businesses is an elusive goal. Two wrongs won't neccessarily make a right.
Ann: Appointment of Independent Non-Executive Director, page-4
Add AT1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.06M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 212890 | 2.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.2¢ | 5440 | 1 |
View Market Depth
| Last trade - 10.07am 15/11/2024 (20 minute delay) ? |
| AT1 (ASX) Chart |
Day chart unavailable